S3V Vascular Technologies, a medical device manufacturer based in Mysore and incubated at the Indian School of Business, has developed a suite of neurovascular devices—including a stent retriever, aspiration catheter, and microcatheter—designed for mechanical thrombectomy procedures. These devices are pivotal in treating acute ischemic strokes by removing blood clots from brain vessels, thereby restoring blood flow and potentially reversing paralysis. Currently, such devices are predominantly imported, costing around ₹4 lakh, whereas S3V aims to offer them at a significantly reduced price of ₹50,000 to ₹75,000, enhancing accessibility for a broader patient population .

 

The TDB’s financial assistance has been instrumental in establishing S3V’s integrated manufacturing facility in Mysore, with an investment of ₹70 crore. This facility is equipped to produce high-quality medical devices, aligning with the ‘Make in India’ initiative and aiming to reduce the country’s dependency on imported medical equipment .

 

 

In addition to government support, S3V has secured approximately ₹300 crore in Series B funding from notable investors, including former L&T chairman A.M. Naik and industry veteran Madhusudan Kela. This investment will further bolster the company’s efforts to establish a state-of-the-art manufacturing facility for neurovascular devices, addressing the rising incidence of strokes in India .

 

The introduction of these indigenous devices is expected to significantly impact stroke treatment in India, where approximately 20 lakh individuals suffer strokes annually, yet only a fraction receive timely interventional procedures. By making advanced treatment more affordable and accessible, S3V’s innovations have the potential to improve outcomes for countless patients .

 

The Technology Development Board (TDB) under the Department of Science & Technology (DST) has extended support to S3V Vascular Technologies for the development of India’s first indigenous mechanical thrombectomy device, marking a significant advancement in stroke care.

Source